title: Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment.
abstract: OBJECTIVE
  To determine whether, as predicted by predator-prey dynamics, early withdrawal of antiretroviral therapy, i.e. when the number of CD4+ lymphocytes is still elevated, results in an overshoot of HIV-1 viraemia due to infection of increased numbers of available target cells at that time.
  
  
  METHODS
  Five HIV-1-infected individuals were identified who discontinued antiretroviral therapy for various reasons after 8-19 days, and from whom stored serum samples obtained before, during, and shortly after treatment were available for measurement of HIV-1 RNA load. A mathematical model was designed to assess whether increased target cell availability could quantitatively explain the clinical observations.
  
  
  RESULTS
  After therapy withdrawal, increases in the HIV-1 RNA load to levels exceeding pretreatment values by log10 0.6-1.5 copies/ml were observed after 2-17 days in all four of the individuals who had treatment-induced increases in CD4+ cell counts at the time of therapy withdrawal. Increases in viraemia were maximal within a few days, and subsequently seemed to wane until the pretreatment equilibrium between virus and its target cells was attained. Mathematical modelling confirms that these transient increases in viraemia can be explained by increased availability of target cells at the time of therapy withdrawal.
  
  
  CONCLUSIONS
  Transient rises in HIV-1 viraemia do occur following early therapy withdrawal. These rises especially warrant consideration in short-term antiretroviral regimens for prevention of mother-to-child transmission, as are being studied in developing countries, since they could result in an increased transmission risk during the post-partum period through breast-feeding. This possibility needs to be investigated urgently.
authors.affiliation: Department of Internal Medicine, University of Amsterdam, The Netherlands.
authors.forename: M D
authors.initials: MD
authors.lastname: de Jong
authors.forename: R J
authors.initials: RJ
authors.lastname: de Boer
authors.forename: F
authors.initials: F
authors.lastname: de Wolf
authors.forename: N A
authors.initials: NA
authors.lastname: Foudraine
authors.forename: C A
authors.initials: CA
authors.lastname: Boucher
authors.forename: J
authors.initials: J
authors.lastname: Goudsmit
authors.forename: J M
authors.initials: JM
authors.lastname: Lange
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D016655:HIV Core Protein p24 / Q000032:analysis; D015658:HIV Infections / Q000188:drug therapy* / Q000635:transmission; D015497:HIV-1; D006801:Humans; D019469:Indinavir / Q000627:therapeutic use; D008954:Models, Biological; D019829:Nevirapine; D011725:Pyridines / Q000627:therapeutic use; D012367:RNA, Viral / Q000032:analysis; D012307:Risk Factors; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis*; D019562:Viral Load; D014766:Viremia / Q000139:chemically induced*; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D016655:HIV Core Protein p24; D011725:Pyridines; D012367:RNA, Viral; D015215:Zidovudine; D019469:Indinavir; D019829:Nevirapine